Amedisys (NASDAQ:AMED) Posts Earnings Results, Beats Estimates By $0.01 EPS

Amedisys (NASDAQ:AMED) released its quarterly earnings results on Wednesday. The health services provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01, Briefing.com reports. The firm had revenue of $571.41 million for the quarter, compared to the consensus estimate of $565.38 million. Amedisys had a positive return on equity of 13.00% and a negative net margin of 0.91%. The firm’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.00 EPS.

Amedisys Stock Performance

Shares of NASDAQ AMED traded up $0.50 during mid-day trading on Friday, hitting $91.66. The company had a trading volume of 39,873 shares, compared to its average volume of 274,900. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.05 and a quick ratio of 1.05. The business’s 50-day simple moving average is $92.57 and its 200-day simple moving average is $93.35. Amedisys has a 12 month low of $73.10 and a 12 month high of $96.44. The firm has a market cap of $2.99 billion, a P/E ratio of -142.84, a PEG ratio of 4.28 and a beta of 0.86.

Analyst Ratings Changes

A number of equities research analysts have recently commented on AMED shares. StockNews.com assumed coverage on Amedisys in a research report on Monday, April 8th. They issued a “buy” rating for the company. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $101.00 target price on shares of Amedisys in a report on Thursday. Royal Bank of Canada upped their target price on Amedisys from $97.00 to $100.00 and gave the stock an “outperform” rating in a research report on Monday, March 25th. Finally, Raymond James restated a “market perform” rating on shares of Amedisys in a research report on Tuesday, March 26th. Seven equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $97.50.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.